Disrupting The Cycle

Emily BurkeClinical Trials, Deoxyribonucleic Acid (DNA), Diabetes, Drug Development, Drug Targets, Mechanism of Action, Small Molecule Drugs, The WEEKLY

Circadian Rhythms Govern More Than 24 Hours Of Your Day Overnight shift workers, students pulling an all-nighter to cram for a final exam, and business people rushing between time zones all share one thing in common: significant disruption to their circadian rhythm. This roughly 24-hour activity cycle responds primarily to light and darkness and is found in most living organisms—people, … Read More

Two Monoclonal Antibodies Walk Into The Market

Emily BurkeBiologics, Clinical Trials, Drug Approvals, Drug Development, Drug Targets, Easily Confused, Mechanism of Action, Monoclonal Antibodies, Small Molecule Drugs, Term of the Week, The WEEKLY

Attacking Asthma & Pushing Out Psoriasis Two new monoclonal antibodies debuted on the market thanks to FDA approvals last month. Both treat chronic inflammatory conditions: Lilly’s (Indianapolis, IN) Taltz for psoriasis and Teva’s (Petah Tikva, Israel) drug Cinqair for severe asthma. Interestingly enough, having psoriasis is associated with an increased risk of developing asthma according to a study in the British Journal of Dermatology. While these two conditions … Read More

Unmasking Multiple Sclerosis

Emily BurkeBiologics, Biotech Basics, Clinical Trials, Drug Development, Drug Targets, Mechanism of Action, Monoclonal Antibodies, Small Molecule Drugs, The WEEKLY

 Many Channels Available To Impede MS Progression Continuing our series on central nervous system (CNS) disorders—previously covering Alzheimer’s and Huntington’s—we pivot to unmask Multiple Sclerosis this week. Famous faces suffering from Multiple Sclerosis (MS) include former talk show host Montel Williams and Sopranos star Jamie-Lynn Sigler. MS typically occurs in susceptible individuals between the ages of 20 and 50, and there are … Read More